Treatment of Leishmaniasis is always not satisfactory despite advancement all these years. This chapter will discuss the standard treatment options like Amphotericin, oral miltefosine, topical paromycin, add more details about newer emerging drugs and alternative therapies, surgical treatment modalities for resistant cases. Will discuss few information regarding vaccines. Special precautions to be taken while travelling to endemic areas will be discussed. Management protocol for mucocutaneous and visceral type will be highlighted. Side-effects of drugs used in the treatment of Leishmaniasis will be discussed in short and measures to monitor these side effects will be discussed. Long term monitoring of relapse will also be discussed
Major therapeutic obstacles in the, treatment of visceral leishmaniasis (VL) include the alarming in...
Leishmaniasis is a tropical disease caused by aprotozoan which is obligate intracellular parasite be...
SummaryAbout 1.5 million new cases of cutaneous leishmaniasis and 500 000 new cases of visceral leis...
There are significant differences in the progress and approaches to drug development for visceral l...
Leishmaniasis, in its variety of visceral (VL), cutaneous (CL) and mucocutaneous (MCL) forms, direct...
AbstractAlthough there have been significant advances in the treatment of visceral leishmaniasis (VL...
Visceral leishmaniasis is the disease of poor; however availability of only expensive treatment of t...
Leishmaniasis is a dismissed vector-borne tropical contamination thought to be an ailment of poor pe...
Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fa...
Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and ...
Leishmaniasis is a major global health challenge, affecting approximately 12 million of the poorest ...
Visceral Leishmaniasis (VL) is also popularly known as kala-azar which was first reported in early f...
The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, ...
Leishmaniasis is a third most important vector born disease caused by intracellular parasite belongs...
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a glo...
Major therapeutic obstacles in the, treatment of visceral leishmaniasis (VL) include the alarming in...
Leishmaniasis is a tropical disease caused by aprotozoan which is obligate intracellular parasite be...
SummaryAbout 1.5 million new cases of cutaneous leishmaniasis and 500 000 new cases of visceral leis...
There are significant differences in the progress and approaches to drug development for visceral l...
Leishmaniasis, in its variety of visceral (VL), cutaneous (CL) and mucocutaneous (MCL) forms, direct...
AbstractAlthough there have been significant advances in the treatment of visceral leishmaniasis (VL...
Visceral leishmaniasis is the disease of poor; however availability of only expensive treatment of t...
Leishmaniasis is a dismissed vector-borne tropical contamination thought to be an ailment of poor pe...
Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fa...
Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and ...
Leishmaniasis is a major global health challenge, affecting approximately 12 million of the poorest ...
Visceral Leishmaniasis (VL) is also popularly known as kala-azar which was first reported in early f...
The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, ...
Leishmaniasis is a third most important vector born disease caused by intracellular parasite belongs...
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a glo...
Major therapeutic obstacles in the, treatment of visceral leishmaniasis (VL) include the alarming in...
Leishmaniasis is a tropical disease caused by aprotozoan which is obligate intracellular parasite be...
SummaryAbout 1.5 million new cases of cutaneous leishmaniasis and 500 000 new cases of visceral leis...